Ladan Mafakher
-
- vaccines and immunoinformatics approaches 4
- Glycosylation and Glycoproteins Research 2
-
- SARS-CoV-2 and COVID-19 Research 3
-
- Monoclonal and Polyclonal Antibodies Research 5
-
- Computational Drug Discovery Methods 4
-
- Peptidase Inhibition and Analysis 3
-
- Influenza Virus Research Studies 2
-
- Toxin Mechanisms and Immunotoxins 2
- Co-authors
- Mohammad BahadoramMaedeh BarahmanSara BahadoramShakiba HassanzadehMohammad DavoodiLadan Teimoori‐ToolabiElham RismaniBehzad Shahbazi
- Journals
- SHILAP Revista de lepidopterología (1 paper)PLoS ONE (1 paper)Scientific Reports (1 paper)
- Partner nations
- IranNetherlandsItaly
In The Last Decade
Ladan Mafakher
28 papers receiving 382 citations
Hit Papers
Peers
Comparison fields: 5 of 86
- Pulmonary and Respiratory Medicine 121
- Biotechnology 29
- Molecular Biology 219
- Cancer Research 47
- Infectious Diseases 39
Countries citing papers authored by Ladan Mafakher
This map shows the geographic impact of Ladan Mafakher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ladan Mafakher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ladan Mafakher more than expected).
Fields of papers citing papers by Ladan Mafakher
This network shows the impact of papers produced by Ladan Mafakher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ladan Mafakher. The network helps show where Ladan Mafakher may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ladan Mafakher, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 1 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 3 | |
| 7 | 2024 | 3 | |
| 8 | 2023 | 2 | |
| 9 | 2023 | 2 | |
| 10 | 2023 | 1 | |
| 11 | 2023 | 5 | |
| 12 | 2023 | 1 | |
| 13 | 2023 | 5 | |
| 14 | 2022 | 6 | |
| 15 | 2022 | 12 | |
| 16 | 2021 | 3 | |
| 17 | 2021 | 7 | |
| 18 | 2021 | 8 | |
| 19 | 2020 | 3 | |
| 20 | 2019 | 19 |
About Ladan Mafakher
Ladan Mafakher is a scholar working on Biotechnology, Immunology and Hematology, having authored 33 papers that have together received 386 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (5 papers), vaccines and immunoinformatics approaches (4 papers), Computational Drug Discovery Methods (4 papers), SARS-CoV-2 and COVID-19 Research (3 papers), Peptidase Inhibition and Analysis (3 papers), Glycosylation and Glycoproteins Research (2 papers), Influenza Virus Research Studies (2 papers) and Toxin Mechanisms and Immunotoxins (2 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (121 citations), Biotechnology (29 citations) and Molecular Biology (219 citations). Ladan Mafakher has collaborated with scholars based in Iran, Netherlands and Italy. Frequent co-authors include Mohammad Bahadoram, Maedeh Barahman, Sara Bahadoram, Shakiba Hassanzadeh, Mohammad Davoodi, Ladan Teimoori‐Toolabi, Elham Rismani, Behzad Shahbazi, Farshad Darvishi and Giti Emtiazi. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.